Two- and three-dimensional rings in drugs

Chemical Biology and Drug Design

Volumn 83, Issue 4, 2014, Pages 450-461

  Aldeghi, Matteo ^a   Malhotra, Shipra ^a   Selwood, David L ^a   Chan, Ah Wing Edith ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

drug; fragment; lead optimization; ring

Indexed keywords

CELL NUCLEUS RECEPTOR; CELL PROTEIN; G PROTEIN COUPLED RECEPTOR; HYDROLASE; ION CHANNEL; ISOMERASE; LIGAND; LIGASE; LYASE; NUCLEIC ACID; OXIDOREDUCTASE; PENICILLIN BINDING PROTEIN; TRANSFERASE; HETEROCYCLIC COMPOUND; INDINAVIR;

ARTICLE; CONTROLLED STUDY; DRUG INFORMATION; DRUG MARKETING; DRUG SHAPE; DRUG STRUCTURE; LIGAND BINDING; MOLECULAR WEIGHT; PHARMACOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; THREE DIMENSIONAL RING FRAGMENT; TWO DIMENSIONAL RING FRAGMENT; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT;

DRUG DISCOVERY; HETEROCYCLIC COMPOUNDS; INDINAVIR; LIGANDS; MOLECULAR STRUCTURE;

EID: 84898999830     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12260     Document Type: Article

References (20)

1. Murray C.W., Verdonk M.L., Rees D.C., (2012) Experiences in fragment-based drug discovery. Trends Pharmacol Sci; 33: 224-232.
2. Scott D.E., Coyne A.G., Hudson S.A., Abell C., (2012) Fragment-based approaches in drug discovery and chemical biology. Biochemistry; 51: 4990-5003.
3. Congreve M., Carr R., Murray C., Jhoti H., (2003) A 'rule of three' for fragment-based lead discovery? Drug Discov Today; 8: 876-877. (Pubitemid 37194496)
4. Congreve M., Chessari G., Tisi D., Woodhead A.J., (2008) Recent developments in fragment-based drug discovery. J Med Chem; 51: 3661-3680. (Pubitemid 351956496)
5. Hung A.W., Ramek A., Wang Y., Kaya T., Wilson J.A., Clemons P.A., Young D.W., (2011) Route to three-dimensional fragments using diversity-oriented synthesis. Proc Natl Acad Sci USA; 108: 6799-6804.
6. Muncipinto G., Kaya T., Wilson J.A., Kumagai N., Clemons P.A., Schreiber S.L., (2010) Expanding stereochemical and skeletal diversity using petasis reactions and 1,3-dipolar cycloadditions. Org Lett; 12: 5230-5233.
7. Lovering F., Bikker J., Humblet C., (2009) Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem; 52: 6752-6756.
8. Galloway W.R., Isidro-Llobet A., Spring D.R., (2010) Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. Nat Commun; 1: 80.
9. Roughley S.D., Jordan A.M., (2011) The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. J Med Chem; 54: 3451-3479.
10. Sauer W.H., Schwarz M.K., (2003) Molecular shape diversity of combinatorial libraries: a prerequisite for broad bioactivity. J Chem Inf Comput Sci; 43: 987-1003.
11. Ritchie T.J., Macdonald S.J., Young R.J., Pickett S.D., (2011) The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types. Drug Discov Today; 16: 164-171.
12. Ritchie T.J., Macdonald S.J., (2009) The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design? Drug Discov Today; 14: 1011-1020.
13. Clemons P.A., Bodycombe N.E., Carrinski H.A., Wilson J.A., Shamji A.F., Wagner B.K., Koehler A.N., Schreiber S.L., (2010) Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles. Proc Natl Acad Sci USA; 107: 18787-18792.
14. Clemons P.A., Wilson J.A., Dancik V., Muller S., Carrinski H.A., Wagner B.K., Koehler A.N., Schreiber S.L., (2011) Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections. Proc Natl Acad Sci USA; 108: 6817-6822.
15. Chan A.W.E., Laskowski R.A., Selwood D.L., (2010) Chemical fragments that hydrogen bond to Asp, Glu, Arg, and his side chains in protein binding sites. J Med Chem; 53: 3086-3094.
16. Knox C., Law V., Jewison T., Liu P., Ly S., Frolkis A., Pon A., Banco K., Mak C., Neveu V., Djoumbou Y., Eisner R., Guo A.C., Wishart D.S., (2011) DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs. Nucleic Acids Res; 39: D1035-D1041.
17. Cox T.F., (2001) Multidimensional scaling used in multivariate statistical process control. J Appl Stat; 28: 365-378.
18. Overington J.P., Al-Lazikani B., Hopkins A.L., (2006) Opinion-How many drug targets are there? Nat Rev Drug Discov; 5: 993-996. (Pubitemid 44835126)
19. Lipinski C.A., (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol; 44: 235-249. (Pubitemid 32239479)
20. Hou T.J., Xia K., Zhang W., Xu X.J., (2004) ADME evaluation in drug discovery. 4. Prediction of aqueous solubility based on atom contribution approach. J Chem Inf Comput Sci; 44: 266-275.